<DOC>
	<DOC>NCT01711294</DOC>
	<brief_summary>To document impact of EUS-FNA needle size and flexibility on effectiveness of pancreatic cystic lesions (PCL) aspiration, on ability to obtain sufficient material for standard diagnostic testing, and on diagnostic accuracy of EUS-FNA aspirate for differentiation of mucinous (pre-malignant) and non-mucinous cysts.</brief_summary>
	<brief_title>Evaluation of PCLs Using Three EUS-FNA Needles</brief_title>
	<detailed_description />
	<criteria>Pancreatic cystic lesion measuring 13mm or greater in largest diameter. Indicated for EUS evaluation of the PCL including EUSFNA. Age 18 years of age or older. Willing and able to comply with the study procedures and provide written informed consent form to participate in the study. Cysts in which FNA is not indicated based on review by the clinician, including potential concern of blood vessel location relative to the cyst. Requirement for anticoagulation using clopidogril, warfarin, or other long acting antiplatelet agents (with the exception of aspirin) that cannot be safely stopped according to institutional guidelines. Standard contraindications for EUS. Known pancreatic pseudocyst. Pregnancy.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Pancreatic Cystic Lesions</keyword>
	<keyword>PCL</keyword>
	<keyword>EUS-FNA</keyword>
</DOC>